Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
C: Arm Label: Revascularization and Insulin Providing (IP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Procedure: Coronary Artery Bypass, Drug: Insulin, sulfonylurea, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Revascularization and Insulin Sensitizing (IS); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Procedure: Coronary Artery Bypass, Drug: Biguanides, thiazolidinediones, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Medical Therapy and Insulin Providing (IP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, sulfonylurea, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Medical Therapy and Insulin Sensitizing (IS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Biguanides, thiazolidinediones, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Intervention Type: PROCEDURE; Name: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions; Assigned to Arm(s): Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS) | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass; Assigned to Arm(s): Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS) | Intervention Type: DRUG; Name: Biguanides, thiazolidinediones; Assigned to Arm(s): Medical Therapy and Insulin Sensitizing (IS), Revascularization and Insulin Sensitizing (IS) | Intervention Type: DRUG; Name: Insulin, sulfonylurea; Assigned to Arm(s): Medical Therapy and Insulin Providing (IP), Revascularization and Insulin Providing (IP) | Intervention Type: DRUG; Name: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers; Assigned to Arm(s): Medical Therapy and Insulin Providing (IP), Medical Therapy and Insulin Sensitizing (IS), Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS)
D: Arm Label: T2D, Dialysis, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Dialysis, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): T2D, Dialysis, Liraglutide, T2D, Dialysis, Placebo, T2D, Normal kidney function, Liraglutide, T2D, Normal kidney function, Placebo

Answer: B